FCF Payout Ratio: N/A
The FCF payout ratio is N/A.
PODD FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio TTM
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
3.94%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $377.70M | $0 | 0.0% |
| 2024 | $305.40M | $0 | 0.0% |
| 2023 | $70.10M | $0 | 0.0% |
| 2022 | ($38.30M) | $0 | N/A (Loss) |
| 2021 | ($190.80M) | $0 | N/A (Loss) |
| 2020 | ($82.50M) | $0 | N/A (Loss) |
| 2019 | ($72.50M) | $0 | N/A (Loss) |
| 2018 | ($126.45M) | $0 | N/A (Loss) |
| 2017 | ($36.02M) | $0 | N/A (Loss) |
| 2016 | ($6.20M) | $0 | N/A (Loss) |
| 2015 | ($23.16M) | $0 | N/A (Loss) |
| 2014 | ($2.57M) | $0 | N/A (Loss) |
| 2013 | ($3.96M) | $0 | N/A (Loss) |
| 2012 | ($40.05M) | $0 | N/A (Loss) |
| 2011 | ($36.57M) | $0 | N/A (Loss) |
| 2010 | ($42.17M) | $0 | N/A (Loss) |
| 2009 | ($52.46M) | $0 | N/A (Loss) |
| 2008 | ($92.66M) | $0 | N/A (Loss) |
| 2007 | ($60.46M) | $0 | N/A (Loss) |
| 2006 | ($44.96M) | $0 | N/A (Loss) |
| 2005 | ($25.79M) | $0 | N/A (Loss) |
| 2004 | ($15.76M) | $0 | N/A (Loss) |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy